Desaturation During Onyx Embolization.

Irene Asouhidou,Vasilios Katsaridis,Meng Lv,D. Zilianaki,G. Vaidis,Π. Ιωάννου,Gregory M. Georgiadis
DOI: https://doi.org/10.1093/bja/aeq222
IF: 11.719
2010-01-01
British Journal of Anaesthesia
Abstract:Editor—The Onyx Liquid Embolic System (Onyx; Micro Therapeutics, Inc., Irvine, CA, USA) is a new non-adhesive liquid embolic agent and is currently being used at our institution in the embolization of cerebral vascular lesions.1 The disadvantage of Onyx is that it is dissolved in dimethyl sulphoxide (DMSO). Systemic toxicity, such as pulmonary oedema, bronchospasm, bradyarrhythmia, and even cardiac arrest, has been a major concern because of the action potential reducing effects of DMSO.2 There are reports regarding the use of Onyx in the treatment of arteriovenous malformations (AVMs) and dural arteriovenous fistulas (DAVFs) from the operative point of view, but there is little on the anaesthetic experience.
What problem does this paper attempt to address?